12-Month Lobbying Summary - In-house Corporation

Janssen Inc. / Berkeley Vincent, President

Registration Summary

Active - Last Updated: 2023-11-01

Who is lobbying?

Janssen Inc. (Address & business activities)

Berkeley Vincent, President

Received government funding or funding expected in current financial year

Business Relationships

Janssen Inc. is a subsidiary of the following parent companies

Johnson & Johnson (Address information)

Beneficiaries of the Lobbying Activity

Janssen Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

What is being lobbied?

Subject Matters

Budget
Economic Development
Health
Industry
Intellectual Property
International Development
International Trade
Justice and Law Enforcement
Privacy and Access to Information
Research and Development
Science and Technology

Subject Matter Details

Legislative Proposal, Bill or Resolution

Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.

Legislative Proposal, Bill or Resolution, Policies or Program

Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D

Policies or Program

COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
Communications regarding the maintenance of domestic supply of essential drug products.
Incentives and programs to attract and support manufacturing activities in Canada
Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.

Policies or Program, Regulation

Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.

Regulation

An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).
Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.

Who is being lobbied?

Government Institutions

Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Justice Canada (JC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Services and Procurement Canada (PSPC)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

Written communication
Oral communication
Arrange one or more meetings

Who are the lobbyists?

Senior Officers whose lobbying activities represent less than 20% of their Duties

Berkeley Vincent, President | No public offices held
Dozie Amuzie, Head of JLABS Canada | No public offices held
Katherine Tsokas, Vice President Regulatory, Quality, Risk Management and Drug Safety | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Jim Pimblett, Director, Government Affairs and Policy | Designated public offices held

Lobbyists in previous versions
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Sylvain Baril, Manager, Strategic Access | No public offices held
- Roberta Kramchynsky, Senior Manager, Government Affairs and Policy | Public offices held

Registration number: 953569-14483
View all registrations versions

Monthly Communication Reports

What oral and arranged communications have taken place?

What oral and arranged communications have taken place?
Date	DPOH, Position Title \| Government Institution	Subject Matters
2024-03-26	Ritu Banerjee, Assistant Deputy Minister Innovation, Science and Economic Development Canada (ISED)	Health, Industry
2023-12-12	Jennifer Miller, Assistant Secretary to Cabinet Privy Council Office (PCO)	Health, Industry
2023-11-21	Chris Johnstone, Assistant Deputy Minister Health Canada (HC)	Health, Industry
2023-11-06	Stan Kutcher, Senator Senate of Canada	Health, Industry
2023-11-06	Andrew Cardozo, Senator Senate of Canada	Health, Industry
2023-11-06	Ben Chin, Senior Advisor Prime Minister's Office (PMO)	Health, Industry
2023-11-06	Stephen Lucas, Deputy Minister Health Canada (HC)	Health, Industry
2023-10-24	Ritu Banerjee, Assistant Deputy Minister Innovation, Science and Economic Development Canada (ISED) Chris Johnstone, Assistant Deputy Minister Health Canada (HC) Simon Kennedy, Deputy Minister Innovation, Science and Economic Development Canada (ISED) Stephen Lucas, Deputy Minister Health Canada (HC)	Health, Industry, Economic Development
2023-09-27	Simon Kennedy, Deputy Minister Innovation, Science and Economic Development Canada (ISED) Stephen Lucas, Deputy Minister Health Canada (HC)	Health, Industry
2023-09-26	Cyndi Jenkins, Chief of Staff \| Office of the Minister of Health, Health Canada (HC)	Health, Industry
2023-09-26	Brian Clow, Deputy Chief of Staff Prime Minister's Office (PMO)	Health, Industry

View all monthly communication reports

Janssen Inc. - Address & business activities

Address:

19 Green Belt Drive
Toronto, ON M3C 1L9
Canada

Telephone number: 416-382-4856

Contact information in previous versions
- 19 Green Belt Drive
  Toronto, ON M3C 1L9
  Canada
  
  Telephone number: 416-382-5082
- 19 Green Belt Drive
  Toronto, ON M3C 1L9
  Canada
  
  Telephone number: 416-449-9444
  
  Fax number: 416-449-2658
- 19 Green Belt Drive
  Toronto, ON M3C 1L9
  Canada
  
  Telephone number: 416-449-9444
  
  Fax number: 416-449-2658

Description of activities:
Janssen Inc. is a subsidiary of US based Johnson & Johnson and is bio pharmaceutical company focused on the sales, marketing and distribution of innovative medicines. Janssen Inc. has no subsidiary companies, although another entity, Johnson & Johnson (Canada) Inc., which is also registered to lobby federally, may have a direct interest in its lobbying.

Descriptions of the corporation's activity in previous versions:
- Research based bio-pharmaceutical company Research and development, sales and marketing of innovative drugs
- Research based bio-pharmaceutical company Resarch and development, sales and marketing of innovative drugs
- Research based pharmaceutical company Resarch and development, sales and marketing of innovative drugs
- Research based pharmaceutical company

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Director of Parliamentary Affairs/Executive Assistant to the Leader of the Opposition House of Commons, Office of the Leader of the Opposition	July 2009 to May 2010	May 31, 2010
Executive Assistant to the Prime Minister Prime Minister's Office, PMO	December 2003 to February 2006	Not a designated office
Legislative Assistant to the Minister of Finance Finance Canada, Office of the Minister of Finance	January 2000 to June 2002	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Director of Parliamentary Affairs/Executive Assistant to the Leader of the Opposition House of Commons, Office of the Leader of the Opposition	July 2009 to May 2010	May 31, 2010
Executive Assistant to the Prime Minister Prime Minister's Office, PMO	December 2003 to February 2006	Not a designated office
Legislative Assistant to the Minister of Finance Finance Canada, Office of the Minister of Finance	January 2000 to June 2002	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant House of Commons, Office of Ted Menzies, MP	September 2006 to November 2007	Not a designated office
Member's Assistant House of Commons, Office of Hon. Carol Skelton, PC, MP	February 2006 to July 2006	Not a designated office
Administrative Assistant House of Commons, Office of the Leader of the Opposition	September 2004 to July 2006	Not a designated office

Date Modified:: 2024-04-04

Search and menus

Language selection

12-Month Lobbying Summary - In-house Corporation

Janssen Inc. / Berkeley Vincent, President

Who is lobbying?

Janssen Inc. (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Janssen Inc. is a subsidiary of the following parent companies

Beneficiaries of the Lobbying Activity

What is being lobbied?

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Policies or Program

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Policies or Program

Policies or Program, Regulation

Regulation

Who is being lobbied?

Government Institutions

Communication techniques

Who are the lobbyists?

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

What oral and arranged communications have taken place?